G18 Search remdesivir gilead

https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course (Odds Ratio: 0.75 [95% CI 0.51 – 1.12] on Day 14). No ...

https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19#

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course (Odds Ratio: 0.75 [95% CI 0.51 – 1.12] on Day 14). No ...

https://www.askgileadmedical.com/

Home | Gilead Medical Information

Committed to improving the lives of patients, Gilead Medical Information strives to provide US healthcare professionals with scientific and clinical information about our products. Search our library of medical knowledge that’s available 24/7. This site is intended as an educational resource for

healthcare professionals practicing in the US. It may include information about products or uses that have not been approved by the US FDA. GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. ...

https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-data-from-remdesivir-study-in-patients-with-severe-covid-19-in-china

Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China

Foster City, Calif., April 23, 2020 – Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences: “Today, information from the first clinical study evaluating the investigational antiviral remdesivir in patients with severe COVID-19 disease in China was prematurely posted on the World Health Organization website. This information has since been removed, as the study investigators did not provide permission for the publication of the results. Furthermore, we believe the post included inappropriate ...

https://www.amerisourcebergen.com/coronavirus-covid-19-information

Coronavirus (COVID-19) Information

We use cookies and tracking technologies to offer you a better browsing experience, analyze site traffic, and improve the website. By clicking “Accept Cookies”, you expressly agree to our use of cookies and tracking technologies in accordance with our Cookie Policy. If you wish to prevent your data from being used by Google Analytics you can opt-out below. On May 1, 2020, the FDA granted an Emergency Use Authorization (EUA) for Gilead’s remdesivir for the treatment of COVID-19. Gilead has ...

https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-request-to-rescind-remdesivir-orphan-drug-designation

Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

Gilead has submitted a request to the U.S. Food and Drug Administration to rescind the orphan drug designation it was granted for the investigational antiviral remdesivir for the treatment of COVID-19 and is waiving all benefits that accompany the designation. Gilead is confident that it can maintain an expedited timeline in seeking regulatory review of remdesivir, without the orphan drug designation. Recent

engagement with regulatory agencies has demonstrated that submissions and review relating to remdesivir for the treatment of COVID-19 ...

https://www.statnews.com/2020/05/04/how-gilead-drug-remdesivir-works-against-coronavirus/

How does Gilead's drug remdesivir work against the coronavirus?

Gilead Sciences' experimental drug remdesivir has been gaining traction as a potential Covid-19 treatment, and late last week scored an emergency use authorization from federal regulators for it to be used in patients with the condition. Preliminary data released last week from a closely watched trial run by the National Institute of Allergy and Infectious Diseases showed that Covid-19 patients who were given remdesivir recovered faster than those who received a placebo. Remdesivir was originally created as a general antiviral ...

https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus

Gilead Sciences Statement on the Company's Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV) | Gilead

Foster City, Calif., January 31, 2020 — Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences: "Gilead is working closely with global health authorities to respond to the novel coronavirus (2019-nCoV) outbreak through the appropriate experimental use of our investigational compound remdesivir. Together with the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and Human Services (DHHS), the U.S. Department ...